The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Open accessAbstract
Background Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK -positive NSCLC are lacking. Methods We conducted a global, phase 3, open-label, randomized trial in which patients with completely resected, ALK -positive NSCLC of stage IB (tumors ≥4 cm), II, or IIIA (as classified according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer and Union for International Cancer Control) were randomly assigned in a 1:1 ratio to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was disease-free survival, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat population. Other end points included central nervous system (CNS) disease–free survival, overall survival, and safety. Research Summary Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer Results In total, 257 patients were randomly assigned to receive alectinib (130 patients) or chemotherapy (127 patients). The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001) and 93.6% and 63.7%, respectively, in the intention-to-treat population (hazard ratio, 0.24; 95% CI, 0.13 to 0.43; P<0.001). Alectinib was associated with a clinically meaningful benefit with respect to CNS disease–free survival as compared with chemotherapy (hazard ratio for CNS disease recurrence or death, 0.22; 95% CI, 0.08 to 0.58). Data for overall survival were immature. No unexpected safety findings were observed. Conclusions Among patients with resected ALK -positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann–La Roche; ALINA ClinicalTrials.gov number, NCT03456076 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E. E., Nicholson, A. G., Groome, P., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,607
Self-citationThe National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Self-citationPostmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
Self-citationFelip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Barlesi, F., Mazieres, J., Merlio, J.-P., Debieuvre, D., Mosser, J., Lena, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,004
Self-citationHida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Self-citationMok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.478 · Cited by 686
Self-citationOverall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 672
Self-citationGarassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E., Mahadevan, A., Floyd, S. R., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 534
Remon, J., Soria, J.-C., & Peters, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1994 · Cited by 470
Herbst, R. S., Wu, Y.-L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., Laktionov, K., Kim, S.-W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02186 · Cited by 408
Self-citationGadgeel, S., Peters, S., Mok, T., Shaw, A. T., Kim, D. W., Ou, S. I., Pérol, M., Wrona, A., Novello, S., Rosell, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy405 · Cited by 318
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 316
Survival After Recurrent Nonsmall-Cell Lung Cancer After Complete Pulmonary Resection
Sugimura, H., Nichols, F. C., Yang, P., Allen, M. S., Cassivi, S. D., Deschamps, C., Williams, B. A., & Pairolero, P. C. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.08.046 · Cited by 293
Zhou, C., Kim, S.-W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J.-J., Cheng, Y., Lee, S.-H., Bu, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30053-0 · Cited by 273
Self-citationZhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1486 · Cited by 228
Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer
Taylor, M. D., Nagji, A. S., Bhamidipati, C. M., Theodosakis, N., Kozower, B. D., Lau, C. L., & Jones, D. R. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.03.031 · Cited by 220
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.
Martin, J., Ginsberg, R. J., Venkatraman, E. S., Bains, M. S., Downey, R. J., Korst, R. J., Kris, M. G., & Rusch, V. W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.092 · Cited by 195
Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., De Petris, L., Kim, D.-W., Chiappori, A., Moro-Sibilot, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4639 · Cited by 191
Is follow-up of lung cancer patients after resection medically indicated and cost-effective?
Walsh, G. L., O'Connor, M., Willis, K. M., Milas, M., Wong, R. S., Nesbitt, J. C., Putnam, J. B., Lee, J. J., & Roth, J. A. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00893-4 · Cited by 190
Self-citationLung Cancer Prognosis Before and After Recurrence in a Population-Based Setting
Consonni, D., Pierobon, M., Gail, M. H., Rubagotti, M., Rotunno, M., Goldstein, A. M., Goldin, L. R., Lubin, J. H., Wacholder, S., Caporaso, N. E., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv059 · Cited by 138
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, A., Passaro, A., Malapelle, U., Banna, G. L., Subbiah, V., & Friedlaender, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102179 · Cited by 119
Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., Goto, K., Daga, H., Ikeda, N., Sugio, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02674 · Cited by 112
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer
Chaft, J. E., Dagogo‐Jack, I., Santini, F. C., Eng, J., Yeap, B. Y., Izar, B., Chin, E. N., Jones, D. R., Kris, M. G., Shaw, A. T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.020 · Cited by 57
Zou, Z., Xing, P., Hao, X., Wang, Y., Song, X., Li, S., Zhang, C., Liu, Z., Ma, K., Dong, G., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02207-x · Cited by 49
Early-stage ALK-positive lung cancer: a narrative review
Chen, M. F., & Chaft, J. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-631 · Cited by 47
Tian, H., Zhang, X., Yang, J., Guo, W., Chen, Z., Zhen, W., & Wu, Y.-L. L. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.001 · Cited by 43
Self-citationCHOUAID, C., Danson, S. J., Andreas, S., Siakpere, O., Benjamin, L., Ehneß, R., Dramard-Goasdoue, M.-H., Barth, J., Hoffmann, H., Potter, V. A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.042 · Cited by 43
Dziadziuszko, R., Peters, S., Ruf, T., Cardona, A. F., Guerini, E., Kurtsikidze, N., Smoljanović, V., & Planchard, D. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100612 · Cited by 34
Self-citationCombination Therapy for EGFR -Mutated Lung Cancer
Wu, Y.-L. L. C., & Zhou, Q. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2311559 · Cited by 27
Self-citationCella, D. F., Wen, P. Y., Ervin, C. M., Vallow, S., Gilloteau, I., DeMuro, C., Mordin, M., Agostinho, A. C., & Dine, J. L. (2023) · Cancer Medicine · doi:10.1002/cam4.5975 · Cited by 9
Resectable non-small cell lung cancer: an evolving landscape
Loh, J., Wijaya, S. T., Sooi, K. W. X., Chia, P. L., & Soo, R. A. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-520 · Cited by 2
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Spicer, J. D., Garassino, M. C., Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Chen, K.-N., Dooms, C., Majem, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01756-2 · Cited by 303
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Advances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
Metadata
- Authors
- Wu, Y.-L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J.-S., Zhong, W., Horinouchi, H., Mao, W., Hochmair, M., de Marinis, F., Migliorino, M. R., Bondarenko, I., Lu, S., Wang, Q., Ochi Lohmann, T., Xu, T., Cardona, A., Ruf, T., Noe, J., & Solomon, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-11
- Volume
- 390
- Issue
- 14
- Pages
- 1265-1276
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394675771
- Cited by
- 431
- References
- 38
- FWCI
- 109.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.